ATE361064T1 - Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte - Google Patents

Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte

Info

Publication number
ATE361064T1
ATE361064T1 AT02721243T AT02721243T ATE361064T1 AT E361064 T1 ATE361064 T1 AT E361064T1 AT 02721243 T AT02721243 T AT 02721243T AT 02721243 T AT02721243 T AT 02721243T AT E361064 T1 ATE361064 T1 AT E361064T1
Authority
AT
Austria
Prior art keywords
proteins
aging
formation
end products
diabetes
Prior art date
Application number
AT02721243T
Other languages
English (en)
Inventor
Samuel Rahbar
Iraj Lalezari
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of ATE361064T1 publication Critical patent/ATE361064T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/762—Organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
AT02721243T 2001-03-08 2002-03-06 Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte ATE361064T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/800,976 US6605642B2 (en) 1999-04-05 2001-03-08 Inhibitors of formation of advanced glycation endproducts (AGES)

Publications (1)

Publication Number Publication Date
ATE361064T1 true ATE361064T1 (de) 2007-05-15

Family

ID=25179864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721243T ATE361064T1 (de) 2001-03-08 2002-03-06 Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte

Country Status (8)

Country Link
US (1) US6605642B2 (de)
EP (1) EP1370256B1 (de)
JP (1) JP4236247B2 (de)
AT (1) ATE361064T1 (de)
AU (1) AU2002252184B2 (de)
CA (1) CA2438870C (de)
DE (1) DE60219894T2 (de)
WO (1) WO2002072083A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7030133B2 (en) * 1999-04-05 2006-04-18 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
EP1575513A4 (de) * 2002-08-16 2007-04-04 Wyeth Corp Zusammensetzungen und verfahren zur behandlung von mit rage zusammenhängenden erkrankungen
JP5044122B2 (ja) * 2003-10-24 2012-10-10 株式会社明治 後期糖化最終生成物形成の新規阻害剤及びアルドース還元酵素阻害剤
EP1682114A2 (de) * 2003-10-27 2006-07-26 City of Hope Verfahren zur senkungen der lipidspiegel in einem säugetier
EP1680397A2 (de) * 2003-10-28 2006-07-19 Dr. Reddy's Laboratories Ltd. Neue verbindungen und deren verwendung als antidiabetische und hypolipidämische mittel, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
SG161242A1 (en) * 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
JP5314428B2 (ja) * 2005-12-23 2013-10-16 ジーコデール システムズ アクチボラゲット 測位用パターン
EP1989227A2 (de) * 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage-fusionsproteine und anwendungsverfahren
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
DE102007041232A1 (de) 2007-08-30 2009-03-05 Henkel Ag & Co. Kgaa Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs
TW200900072A (en) * 2007-03-22 2009-01-01 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
KR101595634B1 (ko) * 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
US8124655B2 (en) * 2007-06-15 2012-02-28 City Of Hope Use of LR-90 and LR-102 to overcome insulin resistance
DE102007054653A1 (de) 2007-11-14 2009-05-20 Henkel Ag & Co. Kgaa Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20120071502A1 (en) * 2010-09-17 2012-03-22 Cell Viable Corporation Novel phenoxyisobutyric acid compounds and methods for synthesis
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
EP2782902A4 (de) * 2011-11-23 2015-08-26 Jill S Fabricant Derivate aus phenoxyisobuttersäure

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100919A (en) 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5272176A (en) 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
DE3410927A1 (de) 1984-03-24 1985-10-03 Hoechst Ag, 6230 Frankfurt Vollaromatische polyester, verfahren zu ihrer herstellung und entsprechende formkoerper
US5268500A (en) 1987-06-15 1993-12-07 Montefiore Medical Center Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US5093367A (en) 1988-06-15 1992-03-03 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US4921997A (en) 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5677330A (en) 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1995031192A1 (en) 1994-05-16 1995-11-23 Thomas Jefferson University Method and use of agents to inhibit protein polymerization and methods of identifying these agents
US5661139A (en) 1995-01-13 1997-08-26 Alteon Inc. Bis-(2-aryl) hydrazones
US5962651A (en) 1995-01-27 1999-10-05 Montefiore Medical Center Modified hemoglobin and its use as a component of an artificial blood substitute
US5602277A (en) 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5716987A (en) 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
CA2368688C (en) 1999-04-05 2009-08-11 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts

Also Published As

Publication number Publication date
US20020013256A1 (en) 2002-01-31
EP1370256B1 (de) 2007-05-02
US6605642B2 (en) 2003-08-12
JP4236247B2 (ja) 2009-03-11
CA2438870A1 (en) 2002-09-19
CA2438870C (en) 2010-11-23
AU2002252184B2 (en) 2006-11-30
WO2002072083A1 (en) 2002-09-19
EP1370256A1 (de) 2003-12-17
DE60219894T2 (de) 2008-01-17
DE60219894D1 (de) 2007-06-14
JP2004532195A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
DE60219894D1 (de) Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte
ATE260099T1 (de) Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
EP1128830A4 (de) Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen
DE69629176D1 (de) Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
WO2004071416A3 (en) Novel inhibitors of formation of advanced glycation endproducts (ages)
Yankeelov Jr Modification of arginine in proteins by oligomers of 2, 3-butanedione
KR910021221A (ko) 정장작용을 갖는 식품조성물
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
BRPI0406427A (pt) Processo para a preparação de roflumilast
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
MXPA02012151A (es) Metodo para purificar una composicion que contiene al menos un producto de deshidratacion interna para un azucar hidrogenado.
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
ES2193590T3 (es) Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.
ATE458084T1 (de) Behandlung von einer cellulosehaltigen mischung mit einem reduzierenden mittel
NO20083590L (no) Biocidblandinger inneholdende pyrition- og pyrrolderivativer
DK1562444T3 (da) Fremgangsmåde til formindskelse af acrylamidindholdet i varmebehandlede levnedsmidler
AU5915100A (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
Mir et al. Neo-epitopes on methylglyoxal modified human serum albumin lead to aggressive autoimmune response in diabetes
Zhao et al. Fructose-mediated damage to lens α-crystallin: prevention by pyruvate
NO20052422L (no) Stabiliserte, fast tilstand polypeptidpartikler.
CY1106917T1 (el) Συνθεση περιεχουσα προδρομο δυναμενο να υδρολυεται με γλυκοσερεβροζιδαση
ATE311400T1 (de) Isolierung von lectinen
WO2009145424A3 (en) Anti-peptic ulcer composition comprising rice prolamin
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
DE69715218D1 (de) Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties